Passage Bio, Inc. (PASG)

NASDAQ: PASG · IEX Real-Time Price · USD
0.880
-0.041 (-4.48%)
Jul 16, 2024, 10:35 AM EDT - Market open
-4.48%
Market Cap 54.86M
Revenue (ttm) n/a
Net Income (ttm) -84.44M
Shares Out 61.64M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 909,756
Open 0.910
Previous Close 0.921
Day's Range 0.862 - 0.920
52-Week Range 0.575 - 1.790
Beta 1.20
Analysts Strong Buy
Price Target 9.00 (+922.73%)
Earnings Date Aug 5, 2024

About PASG

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 28, 2020
Employees 58
Stock Exchange NASDAQ
Ticker Symbol PASG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for PASG stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 922.73% from the latest price.

Price Target
$9.0
(922.73% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations

3 hours ago - GlobeNewsWire

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

5 weeks ago - GlobeNewsWire

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...

2 months ago - GlobeNewsWire

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...

2 months ago - GlobeNewsWire

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...

3 months ago - GlobeNewsWire

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, March 04, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...

4 months ago - GlobeNewsWire

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

5 months ago - GlobeNewsWire

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

5 months ago - GlobeNewsWire

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

PHILADELPHIA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...

7 months ago - GlobeNewsWire

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

8 months ago - GlobeNewsWire

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

8 months ago - GlobeNewsWire

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (...

9 months ago - GlobeNewsWire

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

9 months ago - GlobeNewsWire

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...

10 months ago - GlobeNewsWire

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

1 year ago - GlobeNewsWire

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

PHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

1 year ago - GlobeNewsWire

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

1 year ago - GlobeNewsWire

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

1 year ago - GlobeNewsWire

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (...

1 year ago - GlobeNewsWire

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, May 11, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (C...

1 year ago - GlobeNewsWire

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system ...

1 year ago - GlobeNewsWire

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...

1 year ago - GlobeNewsWire

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...

1 year ago - GlobeNewsWire

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system ...

1 year ago - GlobeNewsWire

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...

1 year ago - GlobeNewsWire